These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34965383)

  • 1. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
    Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
    Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer.
    Lawrenson K; Li Q; Kar S; Seo JH; Tyrer J; Spindler TJ; Lee J; Chen Y; Karst A; Drapkin R; Aben KK; Anton-Culver H; Antonenkova N; ; Baker H; Bandera EV; Bean Y; Beckmann MW; Berchuck A; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Chang-Claude J; Chenevix-Trench G; Chen A; Chen Z; Cook LS; Cramer DW; Cunningham JM; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Dicks E; Doherty JA; Dörk T; du Bois A; Dürst M; Eccles D; Easton DT; Edwards RP; Eilber U; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goode EL; Goodman MT; Grownwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall E; Hogdall C; Hosono S; Iversen ES; Jakubowska A; James P; Jensen A; Ji BT; Karlan BY; Kruger Kjaer S; Kelemen LE; Kellar M; Kelley JL; Kiemeney LA; Krakstad C; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; Nevanlinna H; McNeish I; Menon U; Modugno F; Moysich KB; Narod SA; Nedergaard L; Ness RB; Azmi MA; Odunsi K; Olson SH; Orlow I; Orsulic S; Weber RP; Pearce CL; Pejovic T; Pelttari LM; Permuth-Wey J; Phelan CM; Pike MC; Poole EM; Ramus SJ; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schildkraut JM; Schwaab I; Sellers TA; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Sucheston L; Tangen IL; Teo SH; Terry KL; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; van Altena AM; Van Nieuwenhuysen E; Vergote I; Vierkant RA; Wang-Gohrke S; Walsh C; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Woo YL; Wu X; Wu AH; Yang H; Zheng W; Ziogas A; Monteiro A; Pharoah PD; Gayther SA; Freedman ML
    Nat Commun; 2015 Sep; 6():8234. PubMed ID: 26391404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
    Lee S; Jun J; Kim WJ; Tamayo P; Howell SB
    Anticancer Res; 2020 Nov; 40(11):6017-6028. PubMed ID: 33109540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.
    Cesaratto L; Grisard E; Coan M; Zandonà L; De Mattia E; Poletto E; Cecchin E; Puglisi F; Canzonieri V; Mucignat MT; Zucchetto A; Stocco G; Colombatti A; Nicoloso MS; Spizzo R
    Cell Death Dis; 2016 Sep; 7(9):e2374. PubMed ID: 27899818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.
    Karst AM; Levanon K; Drapkin R
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7547-52. PubMed ID: 21502498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites.
    Jones MR; Peng PC; Coetzee SG; Tyrer J; Reyes ALP; Corona RI; Davis B; Chen S; Dezem F; Seo JH; Kar S; Dareng E; ; Berman BP; Freedman ML; Plummer JT; Lawrenson K; Pharoah P; Hazelett DJ; Gayther SA
    Am J Hum Genet; 2020 Oct; 107(4):622-635. PubMed ID: 32946763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
    Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL
    BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model.
    Blackman A; Rees AC; Bowers RR; Jones CM; Vaena SG; Clark MA; Carter S; Villamor ED; Evans D; Emanuel AJ; Fullbright G; O'Malley MS; Carpenter RL; Long DT; Spruill LS; Romeo MJ; Orr BC; Helke KL; Delaney JR
    Cancer Res Commun; 2024 Sep; 4(9):2525-2538. PubMed ID: 39225558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study.
    Yang L; Liu J; Jin Y; Xing J; Zhang J; Chen X; Yu A
    Sci Rep; 2024 May; 14(1):10427. PubMed ID: 38714753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.
    Chhabra R; Rockfield S; Guergues J; Nadeau OW; Hill R; Stevens SM; Nanjundan M
    Sci Rep; 2021 Mar; 11(1):6270. PubMed ID: 33737539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
    Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.
    Coetzee SG; Shen HC; Hazelett DJ; Lawrenson K; Kuchenbaecker K; Tyrer J; Rhie SK; Levanon K; Karst A; Drapkin R; Ramus SJ; ; Couch FJ; Offit K; Chenevix-Trench G; Monteiro AN; Antoniou A; Freedman M; Coetzee GA; Pharoah PD; Noushmehr H; Gayther SA;
    Hum Mol Genet; 2015 Jul; 24(13):3595-607. PubMed ID: 25804953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
    Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
    Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.
    Fridley BL; Jenkins GD; Tsai YY; Song H; Bolton KL; Fenstermacher D; Tyrer J; Ramus SJ; Cunningham JM; Vierkant RA; Chen Z; Chen YA; Iversen E; Menon U; Gentry-Maharaj A; Schildkraut J; Sutphen R; Gayther SA; Hartmann LC; Pharoah PD; Sellers TA; Goode EL
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):529-36. PubMed ID: 22302016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.